Objective: To assess the maternal and neonatal outcomes after expectant management of pre-viable preterm premature rupture of membranes (PPROM).
Introduction
Premature rupture of membranes (PROM) prior to the limit of fetal viability i.e. before 24 weeks gestation is known as "previable PPROM" [1] . The incidence of pre-viable PPROM is low i.e. 4 per 1000 pregnancies [2] , but it is associated with a high rate of maternal and neonatal morbidity and poor neonatal survival.
Pulmonary hypoplasia is a major cause of mortality in previable PPROM neonates. It is known that the canalicular phase of lung development, characterized by the terminal bronchioles development, occurs during 16-25 weeks of gestation [3] . Oligohydramnios during this critical period may result in pulmonary hypoplasia [4] .
The management of pregnancies with pre-viable PPROM remains controversial. Typically, most women with pre-viable PPROM are presented the option of termination of pregnancy (TOP) given the poor neonatal survival and the potential high rate of maternal and neonatal morbidity. Recent publications have shown that the overall survival rates of the pre-viable PPROM neonates have improved due to recent advances in antenatal and neonatal intensive care [2] . This has shifted the trend towards expectant management. There are no clear guidelines that exist regarding the management of pre-viable PPROM. Of note, the American College of Obstetrics and Gynecology does recommend that pre-viable PPROM patients should be counseled regarding the benefits and the risks of expectant management versus TOP. The patient should be provided with the most current data and then encouraged to make an individualized decision [5] .
The purpose of this study was to outline the most up-to-date data on the pregnancy outcomes of pre-viable PPROM following expectant management. In addition, we also tried to describe the predictors for favorable pregnancy outcomes of pre-viable PPROM following expectant management and to determine the proportion of women opting for TOP instead of expectant management when both options were available. This document aims to serve as a guide for counseling of pre-viable PPROM patients and support them to make an individualized decision regarding their choice of expectant management or TOP.
Sources
Four databases were searched: PubMed, Cumulative Index of Nursing and Allied Health Literature (CINAHL), Scopus, and Web of Science. With assistance of an experienced medical librarian, we designed a separate search strategy for each of these databases (Appendix 1). We collected the studies published in English language from January 2008 through March 2018. We also searched ClinicalTrials.gov for completed trials using the keywords "Preterm" and "Rupture. " Furthermore, we handsearched the reference lists of the included studies to find out the additional studies missed by the database search. We followed MOOSE guidelines to report our systematic review [6] .
Study Selection
The identified studies were imported into bibliographic software (EndNote Web). After duplicates were deleted, we screened the titles and abstracts of the identified studies. The full text articles of the screened studies were retrieved using University of California Irvine library system and studies fulfilling the eligibility criteria were selected.
Studies reporting the maternal and neonatal outcomes of PPROM occurring before 24 weeks gestation published in past ten years were included. We excluded review articles and single case studies. We also excluded the studies that exclusively included women with a particular characteristic [e.g. oligohydramnios, prolonged latency (>5 days), or delivery at a particular gestation] or evaluated the effect of a particular intervention (antibiotics, corticosteroids, Amnioinfusion). Among the studies reporting pregnancy outcomes of mid-trimester PPROM (occurring at 14-28 weeks), we excluded those that provided the aggregate data, from which the subjects having PPROM at <24 weeks gestation could not be distinguished.
The selected studies were retrospective cohort studies. We assessed the quality of the selected studies by using Newcastle-Ottawa Quality Assessment Scale for Cohort Studies [7] . This scale assesses the studies in selection, comparability and outcome categories and awards a maximum of 9 stars. As our selected studies did not have any control group, they were not assessed for comparability. In selection category we excluded two items: "selection of non-exposed cohort" (there was no non-exposed group) and "demonstration the outcome was not present at start of study" (perinatal outcomes could not be present before PPROM). So, the maximum number of stars for our review was 5. All of our selected studies had >3 stars and therefore were included.
One author (F.M.) thoroughly read each of the included studies and collected data for the basic characteristics of these studies and primary and secondary outcomes using the predesigned tables. In addition, data was also collected for latency period, predictors for better pregnancy outcomes after expectant management, and the proportion of patients opting for TOP. A second author (A.B.H.) reviewed the collected data for its accuracy. Any disagreement between two authors was resolved by consensus. The study authors were contacted for missing data.
The primary outcome of our research was "neonatal survival to discharge". The secondary outcomes were neonatal and maternal morbidity. Neonatal Morbidity included pulmonary hypoplasia, bronchopulmonary dysplasia (BPD), respiratory distress syndrome (RDS), neonatal sepsis, intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP), and limb contractures. Maternal Morbidity included chorioamnionitis, endometritis, maternal sepsis, cord prolapse, retained placenta, placental abruption, and caesarean delivery. Microsoft Excel was used to integrate the results of included studies. Results were presented in the form of tables and graphs.
Results
Total 1015 articles were identified (PubMed: 443, CINAHL: 200, Scopus: 165, Web of Science: 138, ClinicalTrials.gov: 47, Handsearch: 22). Of these, 38 were selected for full text article review. Finally, 18 articles [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] were included in the review. Figure 1 shows the whole process of study selection, using PRISMA flow diagram [26] .
All of the included studies were conducted at tertiary care centers in 10 developed countries and reported the perinatal outcomes of 1,372 pre-viable PPROM women followingexpectant management. The summary of the basic characteristics of all of these studies is shown in Appendix 2. The range of GA at PPROM being studied varied across the studies (0-24, 14-24, 16-24, 18-24, 20-24, 13-20, 18-26, or 13-27 weeks) . For two studies [15, 25] that also included patients with higher gestations (18-26, or 13-27 weeks), data was extracted only for the subjects with PPROM at <24 weeks. In the reviewed studies, PPROM was diagnosed by a typical history of fluid leakage and speculum examination followed by ultrasound and PROM test. Except two studies where the option of TOP was not available, patients were allowed to choose between TOP and expectant management after counseling. Among women that underwent expectant membrane latency period varied across the studies (Appendix 3).
Neonatal Survival to Discharge
Our reviewed articles studied 1,428pre-viable PPROM fetuses following expectant management. Among them, 923neonates were born alive. Some of these neonates died during their stay in NICU. The overall neonatal survival to discharge rate was 41.5 % (592/1428), with a range of 5-83% among studies (Table 1, Figure 2 ).
Most of the included studies showed that the survival to discharge rate improved significantly with increasing GA at PPROM [14, 15, [17] [18] [19] 25] . van der Marel et al. [14] reportedthat the neonatal survival was significantly better for PPROM at >20 weeks than at <20 Weeks(46.9 vs. 22.7 %, p=0.008). This association remained significant after adjusting for potential confounders (adjusted OR: 9.78, 95% CI: 1.85-51.66). Similar association of improved survival with PPROM at >20 weeks was demonstrated by two other studies as well [18, 19] . However, a recent study [8] demonstrated that there was no significant association between neonatal survival and GA at PPROM. This might be the result of type II error due to sample size of the study.
Four studies described oligohydramnios as a predictor of poor neonatal survival [17, 18, 20, 24] . Storness-Bliss et al. reported that the survival rate was seven times lower inoligohydramnios group than non-oligohydramnios group (8.3% vs. 60 %, P=0.02). On contrary, Kibel et al. did not find any significant difference in survival between two groups. Two studies [17, 23] described a positive association of neonatal survival with iatrogenic PPROM and one [17] with CRP<1mg/dl on first admission.
Neonatal Morbidity
The most frequently observed neonatal morbidities were: RDS (49%, range: 26-100%) and BPD (30%, range: 14-48%). Sepsis, IVH, and joint contractures were also observed in a significant proportion of neonates (22.7%, 17.4%, and 17.5% respectively) ( Table 2) .
Overall, 49 percent (range: 27-64%) neonates survived without a major morbidity (Table 2, Figure 3 ). Wagner et al. demonstrated that GA at delivery was the only factor significantly associated with intact survival in a multivariable analysis (adjusted OR: 2.09, 95% CI: 1.20-3.63) (13) . Two other studies also observed a similar association (16, 25) . No other factor was demonstrated to contribute towards intact survival.
Among live born neonates, the rate of the pulmonary hypoplasia varied between 0-30 percent, with a mean of 10.7 (Appendix 4). The predictors of lower rate included later GA at PPROM (20, 25) and higher amniotic fluid index (AFI) levels (25) . Of the surviving neonates that were followed up during their childhood, 25% (range: 19-50%) suffered from some longterm morbidity (Appendix 5). The long-term sequelae included neurological impairment (most common), developmental problems, limb defects, chronic bronchitis, patent ductusarteriosus, pulmonary hypertension, and chronic lung disease.
Maternal Morbidity
Out of 802 pre-viable PPROM women being studied, almost half (49.3%) suffered from clinical chorioamnionitis. Cesarean delivery (34%), placental abruption (30%), and retained placenta (20%) were also frequently observed (Table 3 ). There was no significant predictor of maternal morbidity described in these studies. Oligohydramnios is generally thought to have an association withchorioamnionitis. Storness-Bliss et al. demonstrated that although the rate of chorioamnionitis was higher in women with oligohydramnios than those without oligohydramnios (70%vs.50%), the difference was not statistically significant (p=0.63).
Termination of Pregnancy
Overall, 21.6% (234/1083) of pre-viable PPROM women opted for TOP (Table 4 ). The decision to choose TOP was influenced by: GA at PPROM [12, 14, 18, 25] , AFI levels [12, 17, 23] , and iatrogenic etiology of PPROM [18, 23] . 
Discussion
Our review demonstrates that although 49% pre-viable PPROM women suffered from chorioamnionitis after expectant management, serious complications like sepsis occurred only in 2.9% and no maternal death was reported. Among these women, 41% took home a live baby. Neonates of 20% women survived without a major morbidity. Survival rate improved with increasing GA at PPROM and AFI levels. In light of these findings, women may be counseled regarding expectant management particularly when PPROM occurs after 20 weeks gestation and oligohydramnios is absent. Another important message is that neonatal survival has primarily improved due to advances in maternal and neonatal care, and therefore, all pre-viable PPROM patients should be managed at tertiary care facilities with higher level of NICU care.
The strength of our review is that whole of our data was exclusively collected for PPROM at <24 weeks gestation (age of fetal viability). Sixteen of the reviewed articles solely included women with PPROM at <24 weeks. Although we reviewed two studies that also included women with higher GA at PPROM, but from those we only extracted data for the subjects with PPROM at <24 weeks gestation. Therefore, our results are a true estimate of the maternal and neonatal outcomes after expectant management of pre-viable PPROM. Although some previous reviews tried to calculate pre-viable PPROM outcomes after expectant management, but at that time most of the available studies had focused on mid-trimester PPROM (at 14-28 weeks) instead of the pre-viable PPROM exclusively. Therefore, those reviews also included the studies evaluating PPROM outcomes at higher gestational age (for example: PPROM at <26, 22-25, 16-25+5, etc.) that clouded the results. Moreover, we also reported the proportion of pre-viable PPROM women who opted for TOP instead of expectant management when both options were available.
There are several limitations of our study. We did not include the studies published in non-English language. All of the included studies were retrospective in nature, so accuracy of their data was dependent on the accuracy of available records. These studies were conducted at tertiary care referral centers that may have led to pre-admission selection bias. In the selected studies several women underwent TOP and were excluded from data analysis. Most of these women had risk factors for poor neonatal survival. This may have resulted in overestimation of the survival rate after expectant management. Furthermore, there was great heterogeneity across the selected studies regarding: operational definitions of many study variables (pulmonary hypoplasia, survival without major morbidity, etc.); range of the GA at PPROM of the included patients; exclusion of twin pregnancies and iatrogenic PPROM; and expectant management protocols, which may have affected our results.
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